Clinical efficacy of fixed-dose combination antihypertensive therapy (focus on Hypotef)


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

It is now known that arterial hypertension can lead to fatal complications such as myocardial infarction, stroke, and progression of renal failure up to the terminal stage. Adherence to antihypertensive therapy and achievement of target blood pressure values still remain an important problem of practical cardiology. This article presents the results of a multicenter study on the use of domestic fixed-dose combined antihypertensive drug Hypotef in patients with arterial hypertension of 1-2 degrees. The results of the study indicate a high antihypertensive activity of Hypotef that is similar to the efficacy of enalapril 20 mg/day and metoprolol tartrate 50 mg/day (± indapamide 2.5 mg/day).

Full Text

Restricted Access

About the authors

Anna Grigorievna Yevdokimova

A.I. Yevdokimov Moscow state university of medicine and dentistry

Email: aevdokimova@rambler.ru
MD, professor of the Department of hospital therapy №2

Vladimir Vyacheslavovich Yevdokimov

A.I. Yevdokimov Moscow state university of medicine and dentistry

PhD, associate professor of the Department of hospital therapy №2

Yelena Viktorovna Kovalenko

A.I. Yevdokimov Moscow state university of medicine and dentistry

PhD, associate professor of the Department of hospital therapy №2

Konstantin Inalovich Tebloyev

A.I. Yevdokimov Moscow state university of medicine and dentistry

MD, professor, head of the Department of hospital therapy №2

References

  1. Диагностика и лечение артериальной гипертензии. Клинические рекомендации Российского медицинского общества по артериальной гипертонии 2013 г. Кардиологический вестник. 2015;1:3-30. [Diagnosis and treatment of hypertension. Clinical guidelines of the Russian medical society on arterial hypertension 2013. Cardiac Gazette. 2015;1:3-30 (in Russian)]
  2. Чазова И.Е. По страницам национальных рекомендаций по лечению артериальной гипертензии: какая стратегия лечения артериальной гипертензии важнее. Эффективная фармакотерапия. Кардиология и ангиология. 2015;1(24):32-5. [Chazova I.Ye. Pages of national guidelines for the treatment of hypertension: what strategy for the treatment of hypertension is more important. Effective pharmacotherapy. Cardiology and angiology. 2015;1(24):32-5 (in Russian)]
  3. Bangalore S., Kamalakkannan G., Parkar S., Messerli F.H. Fixed-dose combinations improve medication compliance: a meta-analysis. Am. J. Med. 2007;120:713-9.
  4. Gradman A.H., Parisé H., Lefebvre P., Falvey H., Lafeuille M.H., Duh M.S. Initial combination therapy reduces the risk of cardiovascular events in hypertensive patients: a matched cohort study. Hypertension. 2013;61(2):309-18.
  5. Протокол многоцентрового наблюдательного исследования «Эпидемиология сердечно-сосудистых заболеваний в регионах Российской Федерации» (ЭССЕ-РФ). М., 2012. [Protocol of multicenter observational study «Epidemiology of cardiovascular diseases in regions of the Russian Federation». Moscow, 2012 (in Russian)]
  6. Леонова М.В., Белоусов Д.Ю., Штейнберг Л.Л. и др. Результаты фармакоэпидемиологических исследований артериальной гипертонии ПИФАГОР III, IV. Российский кардиологический журнал. 2015; 1 (117):59-66. [Leonova M.V., Belousov D.Yu., Steinberg L.L. et al. Results of pharmacoepidemiological studies of hypertension PYTHAGORAS III, IV. Russian journal of cardiology. 2015;1(117):59-66 (in Russian)]
  7. Сиренко Ю.Н. Эналаприл в кардиологии и терапии: стандарт эффективности и безопасности среди ингибиторов АПФ. Новости медицины и фармации. 2011;13-14:376-7. [Sirenko Yu.N. Enalapril in cardiology and therapy: a standard of efficiency and safety among the ACE inhibitors. News of medicine and pharmacy. 2011;13-14:376-7 (in Russian)]
  8. Чазов Е.И., Беленков Ю.Н., Борисова Е.О., Гогин Е.Е. и др. Рациональная фармакотерапия сердечно-сосудистых заболеваний. Руководство для практикующих врачей. Под общей редакцией Е.И. Чазова, Ю.Н. Беленкова. М.: Литтерра, 2006. 972 с. [Chazov Ye.I., Belenkov Yu.N., Borisova Ye.A., Gogin Ye.Ye. et al. Rational pharmacotherapy of cardiovascular diseases. Guide for practitioners. Under the general editorship of Ye.I. Chazov, Yu.N. Belenkova. Moscow: Litterra, 2006. 972 p. (in Russian)]
  9. Евдокимова А.Г. Особенности применения эналаприла (Берлиприл®) у больных с артериальной гипертонией. Трудный пациент. 2008;10:5-13. [Evdokimova A.G. Features of the use of enalapril (Berlipril®) in patients with arterial hypertension. Difficult patient. 2008;10:5-13 (in Russian)]
  10. Neaton J.D., Grimm R.H. Jr, Prineas R.J., Stamler J., Grandits G.A., Elmer P.J., Cutler J.A., Flack J.M., Schoenberger J.A., McDonald R. et al. Treatment of mild hypertension study. Final results. JAMA. 1993;270:713-24.
  11. Lindholm L.H., Hansson L. Sweedish trial in old patients with hypertension 2 (STOP-Hypertension 2). Blood Press. 1996;5:300-4.
  12. Fonarow G.C., Stough W.G., Abraham W.T., Albert N.M., Gheorghiade M., Greenberg B.H., O'Connor C.M., Sun J.L., Yancy C.W., Young J.B.; OPTIMIZE-HF Investigators and Hospitals. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J. Am. Coll. Cardiol. 2007;50(8):768-77.
  13. Libretti A., Catalano M. Lipid profile during antihypertensive treatment. The SLIP study. Drugs. 1993;46(Suppl. 2):16-23.
  14. Cuspidi C., Muiesan M.L., Valagussa L. et all. Comparative effects of candesartan and enalapril on LVH in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. J Hypertens 2002;20:2293-300.
  15. Foy S.G., Crozier I.G., Turner J.G., Richards A.M., Frampton C.M., Nicholls M.G., Ikram H. Comparison of enalapril versus captopril on left ventricular function and survival three months after acute myocardial infarction (the PRACTICAL study). Am. J. Cardiol. 1994;73(16):1180-6.
  16. Estacio R.O., Jeffers B.W., Hiatt W.R., Biggerstaff S.L., Gifford N., Schrier R.W. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N. Engl. J. Med. 1998;338:645-52.
  17. PROGRESS Collaborative Group. Randomised trial of perindopril based blood pressure lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033-41.
  18. Patel A. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370:829-40.
  19. Dahlöf B., Gosse P., Guéret P., Dubourg O., de Simone G., Schmieder R., Karpov Y., Garcia-Puig J., Matos L., De Leeuw P. W., Degaute J. P., Magometschnigg D. PICXEL Investigators. Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study. J. Hypertens. 2005;23(1 1):2063-70.
  20. Mourad J., Le Jeune S. Evaluation of high dose of perindopril/indapamide fixed combination in reducing blood pressure and improving endorgan protection in hypertensive patients. Curr. Med. Res. Opin. 2009;25(9):2271-80.
  21. Scholze J. Group for the East Fermany Collabopative Trial. Short report; ramipril and hydrochlorothiazide combination therapy in hypertension: a clinical trial of factorial design. J. Hypertens. 1993;11:217-21. 79
  22. Wing L.M., Reid C.M., Ryan P., Beilin L.J., Brown M.A., Jennings G.L., Johnston C.I., McNeil J.J., Macdonald G.J., Marley J.E., Morgan T.O., West M.J. Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N. Engl. J. Med. 2003;348:583-92.
  23. Чазова И.Е., Ратова Л.Г. Комбинированная терапия у пациентов с артериальной гипертонией. Системные гипертензии. 2010;2:6-10. [Chazova I.Ye., Ratova L.G. Combination therapy in patients with hypertension. Systemic hypertensions. 2010;2:6-10 (in Russian)]
  24. Bangalore S., Kamalakkannan G., Parkar S., Messerli F.H. Fixed-dose combinations improve medication compliance: a meta-analysis. Am. J. Med. 2007;120:713-9.
  25. Marre M., Puig J.G., Kokot F., Fernandez M., Jermendy G., Opie L., Moyseev V., Scheen A., Ionescu-Tirgoviste C., Saldanha M.H., Halabe A., Williams B., Mion Junior D., Ruiz M., Hermansen K., Tuomilehto J., Finizola B., Gallois Y., Amouyel P., Ollivier J.P., Asmar R. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study. J. Hypertens. 2004;22:1613-22.
  26. Kaiser E., Axthelm C., Sieder C., Meister F. A database analysis to evaluate the risk of cardiovascular events in hypertensive patients being treated with either the single pill combination of valsartan and amlodipine or the respective free combination. J. Hypertens. 2011;29(e-Suppl A):e282.
  27. Scholze J., Bramlage P., Trenkwalder P., Kreutz R. Efficacy and safety of a fixed-dosecombination of lercanidipine and enalapril in daily practice. A comparison of office, self-measured and ambulatory blood pressure. Expert Opin. Pharmacother. 2011;12(17):1-9.
  28. Clissold S.P., Brogden R.N. Metoprolol: an updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in hypertension, ischaemic heart disease and related cardiovascular disorder. Drugs. 1986;31(5):376-429.
  29. Белоусов Ю.Б., Леонова М.В., Манешина О.А., Соколов А.В., Тищенкова И.Ф. Метопролола сукцинат и тартрат: влияет ли соль на эффективность препарата. Фарматека. 2006;19:14-9. [Belousov Yu.B., Leonova M.V., Maneshina O.A., Sokolov A.V., Tishchenkova I.F. Metoprolol succinate and tartrate: does salt on the effectiveness of the drug. Pharmateca. 2006;19:14-9 (in Russian)]
  30. Carruthers G., Shearer R., Taylor W., Moore M. A comparison of a controlled release (CR/XL) formulation of metoprolol, once daily, with conventional metoprolol tablets, twice daily? In mild to moderate hypertension. J. Clin. Pharmacol. 1990;30:61-5.
  31. Tuomilehto J., Berglund G. Primary prevention of sudden cardiac death in hypertensive patients. Mortality results from the MAPHY study. Am. J. Hypertens. 1991;4:151-8.
  32. Bristow M.R., Swedberg K. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet. 1993;342:1441-6.
  33. Затейщиков Д.А., Затейщикова А.А. Метопролол в лечении острого коронарного синдрома. РМЖ. 2008; 16:1054. [Zateishchikov D.A., Zateishchikova A.A. Metoprolol in the treatment of acute coronary syndrome. Russian medical journal. 2008;16:1054 (in Russian)]
  34. Billinger M., Seiler C., Fleisch M., Eberli F.R., Meier B., Hess O.M. Do beta-adrenergic blocking agents increase coronary flow reserve? J. Am. Coll. Cardiol. 2001;38(7):1866-71.
  35. Ibanez B., Prat-González S., Speidl W.S., Vilahur G., Pinero A., Cimmino G., Garcia M.J., Fuster V., Sanz J., Badimon J.J. Early metoprolol administration before coronary reperfusion results in increased myocardial salvage: analysis of ischemic myocardium at risk using cardiac magnetic resonance. Circulation. 2007;115:2909-16.
  36. Feigin V., Ratnasabapathy Y., Anderson C. Does blood pressure lowering treatment prevents dementia or cognitive decline in patients with cardiovascular and cerebrovascular disease? J. Neurol. Sci. 2005;229-230:151-5.
  37. Bonoczk P., Gulyas B., Adam-Vizi V., Nemes A., Karpati E., Kiss B., Kapas M., Szantay C., Koncz I., Zelles T., Vas A. Role of sodium channel inhibition in neuroprotection: effect of vinpocetine. Brain Res. Bull. 2000;53:245-54.
  38. Tretter L., Adam-Vizi V. The neuroprotective drug vinpocetine prevents veratridine-induced [Na+]i and [Ca2+]i rise in synaptosomes. Neuroreport. 1998;9:1849-53.
  39. Kiss B., Cai N. S., Erdo S. L. Vinpocetine preferentially antagonizes quisqualate/AMPA receptor responses: evidence from release and ligand binding studies. Eur. J. Pharmacol. 1991;209:109-12.
  40. Miyazaki M. The effect of a cerebral vasodilator, vinpocetine, on cerebral vascular resistance evaluated by the Doppler ultrasonic technique in patients with cerebrovascular diseases. Angiology. 1995;46:53-8.
  41. Hayakawa M. Effect of vinpocetinee on red blood cell deformability in stroke patients. Arzneim-Forsch. 1992;42:425-7.
  42. Nagy Z., Vargha P., Kovacs L. Meta-analysis of cavinton. Praxis. 1998;7:63-8.
  43. Островский А.Б., Алексеенко С.А., Петричко Т.А. Эффективность комбинированной терапии диротоном и кавинтоном у пациентов с артериальной гипертонией и гипертонической энцефалопатией. Гедеон Рихтер в СНГ. 2002;4:36-7. [Ostrovsky A.B., Alekseenko S.A., Petrichko T.A. Efficacy of combination therapy with dirotonom and Cavinton in patients with arterial hypertension and hypertensive encephalopathy. Gedeon Richter in the CIS. 2002;4:36-7 (in Russian)]

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies